Form 4 for SABS SAB Biotherapeutics, Inc.
Accepted 2021-11-16 00:00:00 ET · period of report 2021-10-18 · accession 0001493152-21-028917 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2021-11-16 | 2021-09-28+ | SABS | Beyer Russell P | CFO | A - Grant | $9.07 | +293 | 278 | New | +$2,657 |
| 2021-11-16 | 2021-10-18 | SABS | Beyer Russell P | CFO | A - Grant | $10.10 | +2,475 | 2,475 | New | +$25.0K | |
| I | 2021-11-16 | 2021-10-26 | SABS | Beyer Russell P | CFO | S - Sale | $7.90 | -278 | 0 | -100% | -$2,196 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-29 | A | A | 10 | $10.08 | 15 | I | — | — | (F1) This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. |
| 2 | Common | Common Stock | 2021-10-18 | A | A | 2,475 | $10.10 | 2,475 | D By spouse | — | — | (F1) This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. |
| 3 | Common | Common Stock | 2021-09-28 | A | A | 5 | $10.07 | 5 | I By daughter | — | — | (F1) This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. |
| 4 | Common | Common Stock | 2021-09-28 | A | A | 149 | $10.08 | 149 | I By spouse | — | — | (F1) This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. |
| 5 | Common | Common Stock | 2021-10-25 | A | A | 129 | $7.78 | 278 | I By spouse | — | — | |
| 6 | Common | Common Stock | 2021-10-26 | S | D | 278 | $7.90 | 0 | I By daughter | — | — |